This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Sarna L , Swann S , Langer C , Werner-Wasik M , Nicolaou N , Komaki R , Machtay M , Byhardt R , Wasserman T , Movsas B
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5) :1378-84
PMID: 18501528 URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18501528
AbstractPURPOSE: The purpose of this study is to analyze changes in quality of life (QOL) and symptoms from pretreatment to 6 weeks posttreatment in a Phase III randomized study (Radiation Therapy Oncology Group 9801) of amifostine (AM) vs. no AM in patients with Stages II-III non-small-cell lung cancer receiving paclitaxel and carboplatin as induction and then concurrently with hyperfractionated radiation therapy (RT). METHODS AND MATERIALS: One hundred thirty-eight patients with baseline and 6-week posttreatment QOL data were analyzed. There were no significant differences in baseline demographics between those who did and did not have QOL data. The QOL and symptoms were assessed by using the European Organization for Research and Treatment of Cancer (EORTC) Global QOL and Pain subscales and the EORTC-Lung Cancer-13 symptom tool. Clinically relevant changes in QOL were characterized by 10-point differences in individual scores pre/post treatment. A daily diary of patient-rated difficulty swallowing and a weekly physician-rated dysphagia log (using National Cancer Institute Common Toxicity Criteria) were completed during treatment. Weight loss was monitored. Differences in outcomes were examined according to smoking status, alcohol use, and sex. RESULTS: Patients receiving AM reported significantly greater pain reduction after chemoradiation (34% vs. no AM, 21%), less difficulty swallowing during chemoradiation, and less weight loss than patients not receiving AM. However, physician-rated assessments of dysphagia were not significantly different by treatment arm. There were no other significant changes in QOL or symptoms according to treatment arm, smoking status, alcohol use, or sex. CONCLUSIONS: Patient evaluations of difficulty swallowing and pain suggest benefits from AM use that are distinct from clinician-rated assessments.
NotesSarna, Linda Swann, Suzanne Langer, Corey Werner-Wasik, Maria Nicolaou, Nicos Komaki, Ritsuko Machtay, Mitchell Byhardt, Roger Wasserman, Todd Movsas, Benjamin CA21661/CA/NCI NIH HHS/United States CA32115/CA/NCI NIH HHS/United States U10CA37422/CA/NCI NIH HHS/United States Research Support, N.I.H., Extramural United States International journal of radiation oncology, biology, physics Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1378-84. Epub 2008 May 22.